Studies have shown that starting a high-efficacy DMT like Tysabri earlier in the disease course can also lead to less ...
1d
TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotech company focused on allogeneic gamma-delta T cell therapies, announced it will be delisted from ...
(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...
Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials studying Actimab-A in ...
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
Black women with chronic myeloid leukemia face unique challenges when it comes to diagnosis, treatment, and overall disease ...
The prescribed dosage for Venclexta (venetoclax) may depend on your individual treatment plan. Factors like your medical history and whether you take other medications with Venclexta may affect ...
KURA has guided top-line data for KOMET-001 coming in Q2, 2025, which would be consistent with a readout at ASCO or EHA. We know that this study met its primary endpoint of complete response ...
The first line of innate immunological defense against particles are myeloid-lineage phagocytes, namely macrophages and neutrophils, which recognize/internalize the particles, release inflammatory ...
Acute myeloid leukemia (AML) is a cancer of immature blood cells. When the early myeloid cell matures normally, it will become either a mature white blood cell, red blood cell, or platelet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback